Normally, TGF-Beta soothes the immune system, and some cancers use it to evade attack. It also triggers a signaling cascade ...

ImmunityBio announces US FDA submissions of sBLA for NMIBC papillary disease and EAP for Anktiva to treat lymphopenia: Culver City, Calif Thursday, April 17, 2025, 15:00 Hrs [IST] ...

Researchers used integrated Mendelian randomization in a cohort of over 247,000 individuals to identify 62 plasma proteins associated with breast cancer risk. Nine high-confidence targets, including ...

From wearable baby thermometers to AI-generated digital twins, health tech is moving faster than ever. During the Abu Dhabi ...

A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.

In terms of financial performance, ImmunityBio reported that its Q1 2025 Anktiva unit sales volume grew by 150% over the unit ...

Bacteria naturally present in the human intestine (known as the gut microbiota) can transform cholesterol-derived bile acids into powerful metabolites that strengthen anti-cancer immunity by blocking ...

A supplemental biologics license application has been submitted to the FDA for nogapendekin alfa plus Bacillus ...

Trastuzumab deruxtecan approved to treat adults with HER2-positive cancer that’s spread or can’t be removed by surgery.

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has completed multiple submissions to the FDA including an sBLA for BCG-unresponsive NMIBC in papillary ...

Lead investigational program, NDV-01, for High-Grade Non-Muscle Invasive Bladder Cancer, is being evaluated in a Phase 2 study. In addition, preparations are underway to advance sepranolone, a Phase ...

Patient Diagnosed with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ Treated Once with ...